Key Highlights

  • Arcutis Biotherapeutics (NASDAQ:ARQT) reported third-quarter product Revenue of USD 143.9 million, up 45% from USD 99.2 million, with ZORYVE foam contributing USD 75.1 million, up 51%.
  • Net income was USD 8.8 million against USD 7.4 million a year earlier, and diluted EPS of USD 0.06 matched the prior-year quarter.
  • Selling, general and administrative expense climbed 60% to USD 99.6 million, including USD 16.4 million of extra Marketing and media spending for a new awareness campaign.
  • Cash, restricted cash and marketable securities totaled USD 259.8 million against USD 100.0 million of Loan principal, and an infant atopic dermatitis filing carries a February 23, 2027 target action date.

ZORYVE Demand Lifts Sales While Spending Absorbs the Gain

Arcutis Biotherapeutics (NASDAQ:ARQT) filed its third-quarter 10-Q on November 4, 2026. ZORYVE, the dermatology line at the center of the business, comes as several topical PDE4 inhibitor formulations that are applied once a day and contain no steroids. Net revenue reached USD 143.9 million: the 0.3% cream generated USD 37.8 million, up 24%, the 0.15% cream USD 27.3 million, up 44%, and the 0.05% cream USD 3.7 million following its October 2025 launch. The filing credits patient demand. Operating Income reached USD 9.4 million against USD 8.5 million, meaning sales climbed USD 44.7 million yet operating income shifted by under USD 1 million.

A Campaign and Primary Care Sales Force Push SG&A Up 60%

SG&A increased USD 37.2 million to USD 99.6 million. Marketing, media and celebrity costs, including a campaign called Skin to Believe In, accounted for USD 16.4 million of that, and USD 8.6 million came from compensation as the dermatology sales force expanded and a team was built for primary care and pediatrics. That team replaced the Kowa promotion agreement, which ended January 23, 2026. Research and Development rose 14% to USD 22.4 million on ARQ-234 enrollment, and cost of sales grew USD 3.8 million to USD 12.5 million on higher volumes and royalties. Interest income was USD 2.6 million against USD 3.0 million of interest expense.

Nine-Month Profit, Pipeline Milestones and Funding Runway

Nine-month Net Income reached USD 12.5 million, compared with a USD 33.5 million loss, and revenue increased 55% to USD 379.2 million. The company still carries an accumulated Deficit of USD 1,125.6 million and warns that future profit is uncertain. It does not expect to need new financing for current plans. Regulators have set February 23, 2027 as the decision date for widening ZORYVE cream 0.05% to infants as young as three months, and ARQ-234 dosing is ongoing; the first atopic dermatitis subject entered the multiple ascending dose stage in October 2026. Patents provide exclusivity through 2037 for the cream and 2042 for the foam, and licensing partners cover Greater China, Southeast Asia and Japan. No numeric guidance was given, and ZORYVE cream 0.05% launched in Canada in October 2026.

Where Things Stand

Yes, for now. Arcutis Biotherapeutics (NASDAQ:ARQT) earned only USD 8.8 million because operating expenses rose about USD 43.8 million (calculated), nearly matching the USD 44.7 million revenue gain, with SG&A growing faster than sales. Profitability is positive for both the quarter and nine months, and cash and marketable securities stand at USD 259.8 million. The question is whether spending levels off while ZORYVE grows. Next markers are the February 2027 FDA decision, ARQ-234 progress and the pace of primary care sales.